RxDoctor Payments Data

Megan Simon

Psychiatric/Mental Health · Rushville, INNPI 1689140014

Payments from drug & device makers

$2,611in general payments, 2019–2025

Across 179 payments — averaging $14.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$588
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$507
  • Vanda Pharmaceuticals Inc.$484
  • Axsome Therapeutics, Inc.$219
  • Otsuka America Pharmaceutical, Inc.$187
  • Neurocrine Biosciences, Inc.$165
  • plus $460 from 8 others

What the payments were for

  • Food & beverage$2,44494%
  • Education$1676%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,611 in reported general payments places this provider in the 80th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$6,512
Medicare patients
19
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl62$104,182
AustedoDeutetrabenazine15$104,067
RexultiBrexpiprazole20$29,616
CaplytaLumateperone Tosylate12$20,660
VyvanseLisdexamfetamine Dimesylate13$4,956
Aripiprazole50$2,030
Desvenlafaxine Succinate ErDesvenlafaxine Succinate16$1,569
Valproic AcidValproic Acid (As Sodium Salt)11$1,542
Olanzapine19$1,513
Lamotrigine ErLamotrigine14$1,386
Bupropion XlBupropion Hcl39$1,290
Duloxetine Hcl38$843
Venlafaxine Hcl ErVenlafaxine Hcl24$406
Buspirone Hcl35$393
Prazosin Hcl15$375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Loxapine$70$104,27928 claims
AbbVieVraylar$588$104,18262 claims
Otsuka America Pharmaceutical, Inc.Rexulti$187$29,61620 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$507$20,66012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Rushville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →